Type to search

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology | Pharmtech Focus
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron | Pharmtech Focus
Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S. | Pharmtech Focus